CXCL1 and neoplasm: MiR-520/373 was further analysed and was shown to inhibit NF-κB in estrogen-negative breast cancer cells, which further resulted in downregulation of NF-κB targets such as the pro-inflammatory cytokines IL-6, IL-8, CXCL1, and ICAM-1, leading to the inhibition of tumor-related inflammation, and suppression of tumor growth and metastasis [144].